Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK, Amira Team Up In $425 Million Asthma Collaboration

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal gives GSK rights to Amira’s FLAP inhibitors for the treatment of respiratory and cardiovascular disease.

You may also be interested in...



BMS Bets On Amira's IPF Drug In $325M Acquisition

The deal expands BMS's inflammatory disease holdings while bringing double-digit returns to the six-year-old startup's earliest investors.

BMS Bets On Amira's IPF Drug In $325M Acquisition

The deal expands BMS's inflammatory disease holdings while bringing double-digit returns to the six-year-old startup's earliest investors.

Regulus Is On The Launch “Platform” With $20M Series A Financing

Alnylam, Isis keep ownership of joint venture for now, but status change could bring more investors aboard by 2011.

Topics

Latest News
UsernamePublicRestriction

Register

PS067341

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel